EE05186B1 - 4-halogenated-17-methylene steroids, process for their preparation and pharmaceutical compositions containing them - Google Patents

4-halogenated-17-methylene steroids, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
EE05186B1
EE05186B1 EEP200300087A EEP200300087A EE05186B1 EE 05186 B1 EE05186 B1 EE 05186B1 EE P200300087 A EEP200300087 A EE P200300087A EE P200300087 A EEP200300087 A EE P200300087A EE 05186 B1 EE05186 B1 EE 05186B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
compositions containing
compounds
halogenated
preparation
Prior art date
Application number
EEP200300087A
Other languages
Estonian (et)
Inventor
Menzenbach Bernd
Elger Walter
Droescher Peter
Hillisch Alexander
Kaufmann G�nter
Schweikert Hans-Udo
Mller Gerd
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of EE200300087A publication Critical patent/EE200300087A/en
Publication of EE05186B1 publication Critical patent/EE05186B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5 alpha -reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
EEP200300087A 2000-09-04 2001-08-29 4-halogenated-17-methylene steroids, process for their preparation and pharmaceutical compositions containing them EE05186B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (en) 2000-09-04 2000-09-04 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/009943 WO2002019971A1 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Publications (2)

Publication Number Publication Date
EE200300087A EE200300087A (en) 2005-02-15
EE05186B1 true EE05186B1 (en) 2009-06-15

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300087A EE05186B1 (en) 2000-09-04 2001-08-29 4-halogenated-17-methylene steroids, process for their preparation and pharmaceutical compositions containing them

Country Status (29)

Country Link
EP (1) EP1423407B1 (en)
JP (1) JP2004513084A (en)
KR (1) KR100530816B1 (en)
CN (1) CN1262560C (en)
AT (1) ATE319733T1 (en)
AU (2) AU2002210470B2 (en)
BG (1) BG107594A (en)
BR (1) BR0113618A (en)
CA (1) CA2421302C (en)
DE (2) DE10043846A1 (en)
DK (1) DK1423407T3 (en)
EA (1) EA006387B1 (en)
EE (1) EE05186B1 (en)
ES (1) ES2260294T3 (en)
HK (1) HK1060135A1 (en)
HR (1) HRP20030256A2 (en)
HU (1) HUP0300936A3 (en)
IL (2) IL154666A0 (en)
ME (1) MEP14408A (en)
MX (1) MXPA03001912A (en)
NO (1) NO325012B1 (en)
NZ (1) NZ524485A (en)
PL (1) PL360669A1 (en)
PT (1) PT1423407E (en)
RS (1) RS50305B (en)
SK (1) SK286757B6 (en)
UA (1) UA74592C2 (en)
WO (1) WO2002019971A1 (en)
ZA (1) ZA200301715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (en) * 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
AT12800U1 (en) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag A pharmaceutical preparation for use in the oral contraception of lactose intolerant women

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
WO2002000681A1 (en) * 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
ZA200301715B (en) 2004-08-13
NO20030989D0 (en) 2003-03-03
ATE319733T1 (en) 2006-03-15
EP1423407A1 (en) 2004-06-02
JP2004513084A (en) 2004-04-30
MEP14408A (en) 2010-06-10
NZ524485A (en) 2005-11-25
WO2002019971A9 (en) 2002-08-08
EA200300322A1 (en) 2003-10-30
MXPA03001912A (en) 2004-07-08
HUP0300936A3 (en) 2010-01-28
EP1423407B1 (en) 2006-03-08
SK286757B6 (en) 2009-05-07
CA2421302C (en) 2007-08-14
EA006387B1 (en) 2005-12-29
IL154666A0 (en) 2003-09-17
HK1060135A1 (en) 2004-07-30
KR100530816B1 (en) 2005-11-25
DK1423407T3 (en) 2006-07-03
KR20030028836A (en) 2003-04-10
SK2442003A3 (en) 2003-08-05
UA74592C2 (en) 2006-01-16
YU16403A (en) 2006-05-25
WO2002019971A1 (en) 2002-03-14
NO325012B1 (en) 2008-01-14
IL154666A (en) 2008-12-29
PL360669A1 (en) 2004-09-20
AU2002210470B2 (en) 2006-07-20
PT1423407E (en) 2006-07-31
CN1452628A (en) 2003-10-29
RS50305B (en) 2009-09-08
DE50109175D1 (en) 2006-05-04
BG107594A (en) 2003-09-30
AU1047002A (en) 2002-03-22
HUP0300936A2 (en) 2003-11-28
CA2421302A1 (en) 2003-03-03
BR0113618A (en) 2003-07-15
ES2260294T3 (en) 2006-11-01
DE10043846A1 (en) 2002-04-04
NO20030989L (en) 2003-05-02
HRP20030256A2 (en) 2005-10-31
CN1262560C (en) 2006-07-05
EE200300087A (en) 2005-02-15

Similar Documents

Publication Publication Date Title
UA66861C2 (en) 2-phenyl-1-[4-(2-aminoeihoxy)benzyl]-indole in combination with estrogens, method for treatment and pharmaceutical product
MA26843A1 (en) NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT
HUP0102483A2 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
RS49756B (en) Use of xenon for preparing a pharmaceutical preparation for treating neurointoxications
DE60040547D1 (en) METHOD FOR THE TREATMENT OF BIRCINE RINDE AND THE INSULATION OF NATURAL PRODUCTS THEREOF
DE60330695D1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING 15-HYDROXYTESTOSTERONE AND ITS DERIVATIVES
DE60115274D1 (en) USE OF ANTIPROGESTINES FOR PROPHYLAXIS AND TREATMENT OF HORMONE-RELATED DISEASES
JP2004508317A5 (en)
BR0008437A (en) Steroid sulfatase inhibitors and methods for their manufacture and use
EE05186B1 (en) 4-halogenated-17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
BR9707844A (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination for the preparation of a medicine for the treatment of a relative and absolute androgen deficiency in man
EA200100674A1 (en) CLEDRATES DEHYDROEPIANDROSTERONE AND RELATED PHARMACEUTICAL COMPOSITIONS
HUP0101005A2 (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
RS20050816A (en) Pure d-(17alpha)-13-ethyl-17-hydroxy- 18,19-dinopregn-4-ene- 20-yne-3-one-3e- and-3z-oxime isomers,as well as process for the synthesis of the mixture of isomers and the pure isomers
ATE252849T1 (en) AGENTS FOR STABILIZING FOOD AND COSMETIC PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
NO20022713D0 (en) 14,15-cyclopropane steroids from the 19-norandrostancer series, process for the preparation of the compounds, and pharmaceutical preparations containing the compounds
BR0016092A (en) Compound, use of a compound kit for hormonal contraception in a male, and method of treatment

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100829